Ozone therapy as a component of a comprehensive rehabilitation program for patients after polysegmental pneumonia associated with SARS-CoV2 infection
DOI:
https://doi.org/10.14739/2310-1210.2021.6.233891Keywords:
rehabilitation, ozonotherapy, pneumonia viral, SARS-CoV2 infection, long-term COVID-19Abstract
Aim: to analyze the effectiveness of intravenous ozone therapy in long COVID-19 patients experienced community-acquired polysegmental pneumonia (associated with SARS-CoV2 infection).
Materials and methods. The study involved 42 long COVID-19 individuals aged 41–82 years who underwent rehabilitation after community-acquired polysegmental pneumonia associated with SARS-CoV2 infection. The patients were examined and followed up subjectively (by the G. Borg and PCFS scales) and objectively (oxygen saturation, C-reactive protein, ferritin, D-dimer, urea and creatinine, 6-minute walk test).
All patients received similar medicamentous therapy, and combined intravenous ozone therapy was additionally prescribed to the main group patients (n = 21): an alternate-day infusion of 200 ml ozonized saline at a concentration of 20 mg/ml and major autohemotherapy (100 ml ozonized saline at a concentration of 30 mg/ml mixed with 100 ml of the patient’s blood), 10 sessions per treatment course.
Results. The integrated approach to the complex program of long COVID-19 treatment and rehabilitation for patients after pneumonia associated with SARS-CoV2 infection using intravenous ozone therapy has demonstrated its significant effectiveness based on the objective and subjective findings (P < 0.01).
Twice as many patients in the main group (n = 18) achieved endpoints of the study (absence of dyspnea, normalization of blood biochemical markers and oxygen saturation levels, restoration of exercise tolerance) as compared to the control group (n = 9).
Conclusions. The use of combined intravenous ozone therapy (alternating infusion of ozonized saline and ozonized saline mixed with the patient’s blood) in the rehabilitation program for patients after experienced community-acquired polysegmental pneumonia associated with SARS-CoV2 infection is pathogenetically substantiated, effective and cost-effective addition to complex health recovery tools.
References
Ferraro, F., Calafiore, D., Dambruoso, F., Guidarini, S., & de Sire, A. (2021). COVID-19 related fatigue: Which role for rehabilitation in post-COVID-19 patients? A case series. Journal of Medical Virology, 93(4), 1896-1899. https://doi.org/10.1002/jmv.26717
Spielmanns, M., Pekacka-Egli, A. M., Schoendorf, S., Windisch, W., & Hermann, M. (2021). Effects of a Comprehensive Pulmonary Rehabilitation in Severe Post-COVID-19 Patients. International Journal of Environmental Research and Public Health, 18(5), Article 2695. https://doi.org/10.3390/ijerph18052695
Savielieva-Kulyk, N. O. (2021, February 19). COVID-19: likuvannia za naiavnosti dovhotryvalykh naslidkiv khvoroby [COVID-19: a treatment of long-term consequences of the disease]. Ukrainskyi medychnyi chasopys. https://www.umj.com.ua/article/199563/covid-19-likuvannya-za-nayavnosti-dovgotrivalih-naslidkiv-hvorobi [in Ukrainian].
Puchner, B., Sahanic, S., Kirchmair, R., Pizzini, A., Sonnweber, B., Wöll, E., Mühlbacher, A., Garimorth, K., Dareb, B., Ehling, R., Wenter, J., Schneider, S., Brenneis, C., Weiss, G., Tancevski, I., Sonnweber, T., & Löffler-Ragg, J. (2021). Beneficial effects of multi-disciplinary rehabilitation in postacute COVID-19: an observational cohort study. European Journal of Physical and Rehabilitation Medicine, 57(2), 189-198. https://doi.org/10.23736/S1973-9087.21.06549-7
Singh, S. J., Barradell, A. C., Greening, N. J., Bolton, C., Jenkins, G., Preston, L., & Hurst, J. R. (2020). British Thoracic Society survey of rehabilitation to support recovery of the post-COVID-19 population. BMJ Open, 10(12), Article e040213. https://doi.org/10.1136/bmjopen-2020-040213
Gorna, R., MacDermott, N., Rayner, C., O’Hara, M., Evans, S., Agyen, L., Nutland, W., Rogers, N., & Hastie, C. (2021). Long COVID guidelines need to reflect lived experience. The Lancet, 397(10273), 455-457. https://doi.org/10.1016/S0140-6736(20)32705-7
International Scientific Committee of Ozone Therapy. (March 14, 2020). Potential use of ozone in SARS-CoV-2 / COVID-19. https://isco3.org/officialdocs/
Martínez-Sánchez, G., Schwartz, A., & Donna, V. D. (2020). Potential Cytoprotective Activity of Ozone Therapy in SARS-CoV-2/COVID-19. Antioxidants, 9(5), Article 389. https://doi.org/10.3390/antiox9050389
Franzini, M., Valdenassi, L., Ricevuti, G., Chirumbolo, S., Depfenhart, M., Bertossi, D., & Tirelli, U. (2020). Oxygen-ozone (O2-O3) immunoceutical therapy for patients with COVID-19. Preliminary evidence reported. International Immunopharmacology, 88, Article 106879. https://doi.org/10.1016/j.intimp.2020.106879
Varga, Z., Flammer, A. J., Steiger, P., Haberecker, M., Andermatt, R., Zinkernagel, A. S., Mehra, M. R., Schuepbach, R. A., Ruschitzka, F., & Moch, H. (2020). Endothelial cell infection and endotheliitis in COVID-19. The Lancet, 395(10234), 1417-1418. https://doi.org/10.1016/S0140-6736(20)30937-5
Viebahn-Hänsler, R., León Fernández, O. S., & Fahmy, Z. (2012). Ozone in Medicine: The Low-Dose Ozone Concept-Guidelines and Treatment Strategies. Ozone: Science & Engineering, 34(6), 408-424. https://doi.org/10.1080/01919512.2012.717847
Chekman, I. S., Syrovaya, A. O., Makarov, V. A., Makarov, V. V., Lapshin, V. V., & Shapoval, E. V. (2013). Ozon i ozonoterapiya [Ozone and ozonotherapy]. Tsyfrova drukarnia № 1. [in Russian].
Izadi, M., Cegolon, L., Javanbakht, M., Sarafzadeh, A., Abolghasemi, H., Alishiri, G., Zhao, S., Einollahi, B., Kashaki, M., Jonaidi-Jafari, N., Asadi, M., Jafari, R., Fathi, S., Nikoueinejad, H., Ebrahimi, M., Imanizadeh, S., & Ghazale, A. H. (2021). Ozone therapy for the treatment of COVID-19 pneumonia: A scoping review. International Immunopharmacology, 92, Article 107307. https://doi.org/10.1016/j.intimp.2020.107307
Sharma, A., Shah, M., Lakshmi, S., Sane, H., Captain, J., Gokulchandran, N., Khubchandani, P., Pradeep, M. K., Gote, P., Tuppekar, B., Kulkarni, P., Paranjape, A., Pradhan, R., Varghese, R., Kasekar, S., Nair, V., & Khanbande, U. (2021). A pilot study for treatment of COVID-19 patients in moderate stage using intravenous administration of ozonized saline as an adjuvant treatment-registered clinical trial. International Immunopharmacology, 96, Article 107743. https://doi.org/10.1016/j.intimp.2021.107743
Carda, S., Invernizzi, M., Bavikatte, G., Bensmaïl, D., Bianchi, F., Deltombe, T., Draulans, N., Esquenazi, A., Francisco, G. E., Gross, R., Jacinto, L. J., Moraleda Pérez, S., O’dell, M. W., Reebye, R., Verduzco-Gutierrez, M., Wissel, J., & Molteni, F. (2020). COVID-19 pandemic. What should Physical and Rehabilitation Medicine specialists do? A clinician’s perspective. European Journal of Physical and Rehabilitation Medicine, 56(4), 515-524. https://doi.org/10.23736/S1973-9087.20.06317-0
(n.d.). COVID-19 CO-RADS klasyfikatsiia [CO-RADS Classification of COVID-19]. https://vita-com.kiev.ua/covid-19-co-rads.html [in Ukrainian].
Greenhalgh, T., Knight, M., A’Court, C., Buxton, M., & Husain, L. (2020). Management of post-acute covid-19 in primary care. BMJ, 370, Article m3026. https://doi.org/10.1136/bmj.m3026
Ministry of Health of Ukraine. (2021, April 20). Pro zatverdzhennia Protokolu nadannia reabilitatsiinoi dopomohy patsiientam z koronavirusnoiu khvoroboiu (COVID-19) ta rekonvalestsentam [On approval of the Protocol for providing rehabilitation care to patients with coronavirus disease (COVID-19) and convalescents (No. 771)]. https://moz.gov.ua/article/ministry-mandates/nakaz-moz-ukraini-vid-20042021--771-pro-zatverdzhennja-protokolu-nadannja-reabilitacijnoi-dopomogi-pacientam-z-koronavirusnoju-hvoroboju--covid-19-ta-rekonvalescentam
Ministry of Health of Ukraine. (2020, April 2). Pro zatverdzhennia protokolu «Nadannia medychnoi dopomohy dlia likuvannia koronavirusnoi khvoroby (COVID-19)» [On approval of the Protocol «Provision of medical care for the treatment of coronavirus disease (COVID-19)» (No. 762)]. https://moz.gov.ua/article/ministry-mandates/nakaz-moz-ukraini-vid-2042020--762-pro-zatverdzhennja-protokolu-nadannja-medichnoi-dopomogi-dlja-likuvannja-koronavirusnoi-hvorobi-covid-19
Poznyak, T., Blanco, P. G., Martínez, A. P., Oria, I. C., & Cuevas, Clara-L. S. (2018). Ozone Dosage is the Key Factor of Its Effect in Biological Systems. In J. Derco & M. Koman (Eds.), Ozone in Nature and Practice. IntechOpen. https://www.intechopen.com/chapters/61286
Kogan, E. A., Berezovsky, Yu. S., Protsenko, D. D., Bagdasaryan, T. R., Gretsov, E. M., Demura, S. A., Demyashkin, G. A., Kalinin, D. V., Kukleva, A. D., Kurilina, E. V., Nekrasova, T. P., Paramonova, N. B., Ponomarev, A. B., Radenska-Lopovok, S. G., Semyonova, L. A., & Tertychny, A. S. (2020). Patologicheskaya anatomiya infektsii, vyzvannoi SARS-CoV-2 [Pathological anatomy of infection caused by SARS-COV-2]. Sudebnaya meditsina, 6(2), 8-30. https://doi.org/10.19048/2411-8729-2020-6-2-8-30 [in Russian].
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., Zhao, Y., Li, Y., Wang, X., & Peng, Z. (2020). Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA, 323(11), 1061-1069. https://doi.org/10.1001/jama.2020.1585
Thorp, J. A., Hollonbeck, S. A., Viglione, D. D., Green, P. C., Hodge, J. R., Tamburro, J. A., Tran, T. N., & Glassman, D. S. (2020). Novel therapy for COVID-19 does intravenous ozonated-saline affect blood and tissue oxygenation? Journal of Gynecological Research and Obstetrics, 6(2), 046-050. https://doi.org/10.17352/jgro.000085
Wang, L., Chen, H., Liu, X. H., Chen, Z. Y., Weng, X. D., Qiu, T., Liu, L., & Zhu, H. C. (2014). Ozone oxidative preconditioning inhibits renal fibrosis induced by ischemia and reperfusion injury in rats. Experimental and Therapeutic Medicine, 8(6), 1764-1768. https://doi.org/10.3892/etm.2014.2004
Delgado-Roche, L., Riera-Romo, M., Mesta, F., Hernández-Matos, Y., Barrios, J. M., Martínez-Sánchez, G., & Al-Dalaien, S. M. (2017). Medical ozone promotes Nrf2 phosphorylation reducing oxidative stress and pro-inflammatory cytokines in multiple sclerosis patients. European Journal of Pharmacology, 811, 148-154. https://doi.org/10.1016/j.ejphar.2017.06.017
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
